Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.

Article Details

Citation
Copy to clipboard

Panteri A, Strehlau G, Helbig R, Prost C, Doucette K

Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.

Vet Dermatol. 2016 Feb;27(1):22-e7. doi: 10.1111/vde.12278. Epub 2015 Dec 11.

PubMed ID
26660461 [ View in PubMed
]
Abstract

BACKGROUND: Ciclosporin and oclacitinib are immunomodulators approved for the treatment of canine atopic dermatitis. The administration of a short course of prednisolone at the beginning of ciclosporin therapy hastens the efficacy of this drug; oclacitinib has a rapid antipruritic effect similar to that of prednisolone. OBJECTIVES: To evaluate the oral tolerance of oclacitinib and ciclosporin given concurrently for three weeks. ANIMALS: Two groups of eight beagles. METHODS: Dogs were randomized to receive oclacitinib alone (0.4-0.6 mg/kg twice daily for 14 days then once daily for seven days) or in combination with ciclosporin (5 mg/kg once daily) for three weeks. They were examined every day and adverse events were recorded. Blood samples were collected during the acclimatization phase, weekly during treatment and at the end of the study for haematology, clinical chemistry and coagulation evaluation. RESULTS: There were no abnormal clinical observations following treatment with oclacitinib given alone or concomitantly with ciclosporin, with the exception of diarrhoea in two dogs receiving both drugs. Three dogs from each group experienced transient inappetence; three dogs treated with oclacitinib had mild weight loss. Clinical pathology parameters remained within the reference range for beagle dogs at that facility. CONCLUSIONS AND CLINICAL IMPORTANCE: The concomitant administration of ciclosporin and oclacitinib for three weeks to beagles was well tolerated and was not associated with an increase in the number of adverse events or laboratory abnormalities beyond those associated with oclacitinib given alone.

DrugBank Data that Cites this Article

Drugs